Total Payments
$357,131
2024 Payments
$110,667
Companies
21
Transactions
229
Medicare Patients
535
Medicare Billing
$125,642
Payment Breakdown by Category
Consulting$201,619 (56.5%)
Travel$72,343 (20.3%)
Other$72,238 (20.2%)
Research$7,683 (2.2%)
Food & Beverage$3,248 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $201,619 | 81 | 56.5% |
| Travel and Lodging | $72,343 | 66 | 20.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $49,305 | 9 | 13.8% |
| Honoraria | $22,933 | 7 | 6.4% |
| Unspecified | $7,683 | 15 | 2.2% |
| Food and Beverage | $3,248 | 51 | 0.9% |
Payments by Type
General
$349,448
214 transactions
Research
$7,683
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $95,252 | 73 | $0 (2024) |
| Seagen Inc. | $64,563 | 37 | $0 (2023) |
| Astellas Pharma Europe Ltd | $41,977 | 5 | $0 (2024) |
| Astellas Pharma Inc | $33,960 | 5 | $0 (2023) |
| Seattle Genetics, Inc. | $31,924 | 39 | $0 (2019) |
| PFIZER INC. | $17,522 | 9 | $0 (2024) |
| Janssen Research & Development, LLC | $16,478 | 12 | $0 (2023) |
| Astellas Pharma US Inc | $10,533 | 6 | $0 (2024) |
| Astellas Pharma Global Development | $8,205 | 7 | $0 (2024) |
| Janssen Biotech, Inc. | $5,230 | 7 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $110,667 | 39 | Astellas Pharma Europe Ltd ($41,977) |
| 2023 | $89,425 | 43 | Seagen Inc. ($34,545) |
| 2022 | $22,761 | 12 | Seagen Inc. ($7,852) |
| 2021 | $22,833 | 18 | Seagen Inc. ($7,130) |
| 2020 | $29,572 | 14 | Seagen Inc. ($15,035) |
| 2019 | $32,555 | 43 | Seattle Genetics, Inc. ($22,419) |
| 2018 | $21,935 | 33 | Merck Sharp & Dohme Corporation ($17,039) |
| 2017 | $27,382 | 27 | Merck Sharp & Dohme Corporation ($12,647) |
All Payment Transactions
229 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,662.00 | General |
| 12/16/2024 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,320.00 | General |
| 12/16/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 12/07/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $8,345.20 | General |
| 12/07/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $311.28 | General |
| 12/07/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $259.40 | General |
| 12/07/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $48.09 | General |
| 11/18/2024 | Astellas Pharma Europe Ltd | Padcev (Drug) | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Astellas Pharma Europe Ltd | Padcev (Drug) | Consulting Fee | Cash or cash equivalent | $10,041.00 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Astellas Pharma Europe Ltd | Padcev (Drug) | Consulting Fee | Cash or cash equivalent | $4,875.00 | General |
| Category: Oncology | ||||||
| 10/14/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $610.00 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $610.00 | General |
| Category: ONCOLOGY | ||||||
| 09/13/2024 | PFIZER INC. | PADCEV (Biological) | — | In-kind items and services | $940.00 | Research |
| Study: PADCEV CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 08/25/2024 | Astellas Pharma Europe Ltd | Padcev (Drug) | Travel and Lodging | Cash or cash equivalent | $2,703.00 | General |
| Category: Oncology | ||||||
| 08/20/2024 | Astellas Pharma Europe Ltd | Padcev (Drug) | Travel and Lodging | Cash or cash equivalent | $20,608.00 | General |
| Category: Oncology | ||||||
| 08/07/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,220.00 | General |
| 08/01/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $610.00 | General |
| 07/03/2024 | IMMUNITYBIO, INC. | ANKTIVA (Drug) | Honoraria | Cash or cash equivalent | $2,400.00 | General |
| Category: Immunotherapy | ||||||
| 06/24/2024 | Astellas Pharma US Inc | Padcev (Drug) | Consulting Fee | Cash or cash equivalent | $4,219.00 | General |
| Category: Oncology | ||||||
| 06/24/2024 | Astellas Pharma US Inc | Padcev (Drug) | Travel and Lodging | Cash or cash equivalent | $175.24 | General |
| Category: Oncology | ||||||
| 06/24/2024 | Astellas Pharma US Inc | Padcev (Drug) | Travel and Lodging | Cash or cash equivalent | $128.39 | General |
| Category: Oncology | ||||||
| 05/15/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $8,540.00 | General |
| 05/15/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 05/10/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $10,421.60 | General |
| 05/10/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $176.81 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3) | G1 Therapeutics, Inc. | $3,988 | 3 |
| A Phase 2 Multi Cohort, Open Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48 ADC) in Subjects With HER2 Expressing Locally Advanced Unresectable or Metastatic Urothelial Carcinoma | Seagen Inc. | $1,383 | 7 |
| PADCEV CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | Astellas Pharma Global Development | $483.99 | 2 |
| An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | Astellas Pharma Global Development | $483.45 | 1 |
| A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB ANTIPD-L1 ANTIBODY AS MONOTHERAPY AND IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA | F. Hoffmann-La Roche AG | $404.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 111 | 180 | $88,583 | $18,167 |
| 2022 | 5 | 141 | 192 | $105,984 | $21,602 |
| 2021 | 5 | 136 | 337 | $117,977 | $41,366 |
| 2020 | 5 | 147 | 388 | $135,794 | $44,508 |
Total Patients
535
Total Services
1,097
Medicare Billing
$125,642
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 42 | 87 | $30,536 | $6,884 | 22.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 34 | 58 | $33,137 | $6,553 | 19.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 24 | 24 | $18,636 | $3,609 | 19.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 11 | 11 | $6,274 | $1,121 | 17.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 48 | 83 | $27,916 | $6,835 | 24.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 31 | 46 | $24,638 | $5,688 | 23.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 20 | 20 | $19,808 | $3,321 | 16.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 20 | 20 | $14,898 | $3,140 | 21.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 22 | 23 | $18,724 | $2,619 | 14.0% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2021 | 22 | 106 | $17,596 | $17,027 | 96.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 39 | 84 | $43,985 | $10,759 | 24.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 45 | 95 | $30,916 | $8,029 | 26.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 13 | 35 | $13,265 | $2,956 | 22.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 17 | 17 | $12,215 | $2,596 | 21.2% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2020 | 26 | 137 | $22,742 | $21,873 | 96.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 48 | 136 | $42,436 | $9,159 | 21.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 37 | 78 | $39,490 | $7,299 | 18.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 22 | 23 | $21,390 | $4,090 | 19.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 14 | 14 | $9,736 | $2,086 | 21.4% |
About Peter Odonnell
Peter Odonnell is a Internal Medicine healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2007. The National Provider Identifier (NPI) number assigned to this provider is 1861695819.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Peter Odonnell has received a total of $357,131 in payments from pharmaceutical and medical device companies, with $110,667 received in 2024. These payments were reported across 229 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($201,619).
As a Medicare-enrolled provider, Odonnell has provided services to 535 Medicare beneficiaries, totaling 1,097 services with total Medicare billing of $125,642. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Chicago, IL
- Active Since 06/07/2007
- Last Updated 07/08/2007
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1861695819
Products in Payments
- PADCEV (Biological) $65,486
- Padcev (Drug) $56,221
- Xtandi (Drug) $16,309
- Padcev (Biological) $11,193
- TECENTRIQ (Biological) $9,207
- ASG22 (Biological) $6,670
- Balversa (Drug) $5,230
- PADCEV (Drug) $4,493
- KEYTRUDA (Biological) $3,907
- COSELA (Drug) $3,025
- Trodelvy (Drug) $2,432
- Bavencio (Drug) $2,415
- ANKTIVA (Drug) $2,400
- BAVENCIO (Drug) $2,400
- IMFINZI (Drug) $1,806
- ADCETRIS (Biological) $1,327
- Cosela (Drug) $962.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Chicago
Dr. Myles Wolf, Md, MD
Internal Medicine — Payments: $1.8M
Internal Medicine $1.8M
Dr. Merle Diamond, Md, MD
Internal Medicine — Payments: $1.4M
Internal Medicine $1.4M
Dr. Elizabeth Kiracofe, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Robert Kushner, Md, MD
Internal Medicine — Payments: $549,886
Internal Medicine $549,886
Dr. Adam Stein, M.d, M.D
Internal Medicine — Payments: $503,325
Internal Medicine $503,325
Devalingam Mahalingam, M.d, M.D
Internal Medicine — Payments: $501,247
Internal Medicine $501,247